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ABSTRACT 
Two simple, accurate, novel, safe and precise methods were developed for the simultaneous estimation of poorly water-soluble drugs 
Amlodipine besylate (AMD) and Celecoxib (CLX) in a in-house formulation using 2M sodium benzoate as a hydrotropic solution. AMD and CLX 
show maximum absorbances at 243 and 255 nm, respectively. Sodium benzoate did not show any absorbance above 225 nm and thus no 
interference in the estimation of drugs was seen. AMD and CLX follow Beer’s law in the concentration range of 2-10g/ml and 10-50g/ml (r2 = 
0.9992 and 0.9995). Method-A employs the simultaneous equation method using 243 and 255 nm as two analytical wavelengths; method-B 
employs the absorption ratio method, which uses 243 and 250nm as two analytical wavelengths for estimation of AMD and CLX. The mean 
percent label claims of in-house formulation were found to be 98.74± 0.912and 99.22± 1.012in method-1, 97.89± 0.872and 99.49± 0.903 in 
method 2 for AMD and CLX, respectively. The developed methods were validated according to ICH guidelines and values of accuracy, precision 
and other statistical analysis were found to be in good accordance with the prescribed values therefore both methods can be used for routine 
monitoring of AMD and CLX in industry in the assay of bulk drug and pharmaceutical formulation. 
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INTRODUCTION 
Amlodipine besylate (AMD) chemically [3-ethyl5-
methyl(4RS)-2-[(2-aminoethoxy) methyl]-4- (2-
chlorophenyl)-methyl-1-dihydropyridine-3,5-
dicarboxylatebenzenesulfonate (Figure 1a) is a 
dihydropyridine long acting calcium-channel blocker that 
inhibits the transmembrane influx of calcium ions into 
vascular smooth muscles and cardiac muscles, which in turn 
affects their contractile process and results in reduced blood 
pressure. It is used in the treatment of hypertension and 
angina. 
Amlodipine besylate have an absolute bioavailability of 64 
to90% and half-life of about 30-50 hours1-4. Celecoxib (CLX) 
is chemically designated as 4-[5-(4- methylphenyl)-3-
7(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide 
(Figure 1b) and is a diaryl substituted pyrazole 5, 6. The 
mechanism of action of CLX is believed to be due to 
inhibition of prostaglandin synthesis, primarily via 
inhibition of Cyclooxygenase-2 (Cox-2). It is supplied only in 
tablets and capsules for oral administration. CLX is 
practically insoluble in water which precludes its use in 
parenteral and oral solutions dosage forms7. Formulation of 
lipophilic drugs is frequently hampered by their poor 
aqueous solubility which again can limit their therapeutic 
applications.   
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Figure 1. Chemical structure of (a) Amlodipine besylate 
(b) Celecoxib 
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AMD is official in IP8, BP9. Several analytical methods that 
have been reported for the estimation of amlodipine 
besylate in biological fluids and/or pharmaceutical 
formulations include spectrophotometric10-14, HPLC15-17and 
HPTLC18. A survey of literature showed HPLC methods for 
the estimation of CLX in pharmaceutical preparations19-23 
and in biological fluids24-26. It was also estimated by 
HPTLC27, spectroflurometric28 and densitometric29, 
spectrophotometric30,31 methods. Hydrotropic solubilization 
is the phenomenon by which aqueous solubility of poorly 
water soluble drugs and insoluble drugs increases. Various 
techniques have been employed to enhance the aqueous 
solubility and hydrotropy is one of them. Sodium salicylate, 
sodium benzoate, urea, nicotinamide, sodium citrate and 
sodium acetate are the most common examples of 
hydrotropic agents utilized to increase the water solubility 
of the drug. Maheshwari32,33 and Jain et al34-43 have analyzed 
various poorly water-soluble drugs using hydrotropic 
solubilization phenomenon for single drug or in combination 
viz. Frusemide, ketoprofen, amlodipine besylate, 
pramipexole dihyrochloride, olmesartan maedoxamil, 
lomefloxacin, furazolidone, entacapone, metronidazole & 
Ofloxacin, Ornidazole, Tinidazole, Metronidazole & 
Furazolidone. Various organic solvents such as methanol, 
chloroform, dimethyl formamide and acetonitrile have been 
employed for solubilization of poorly water-soluble drugs to 
carry out spectrophotometric analysis. Drawbacks of organic 
solvents include their higher cost, toxicity and pollution. 
Hydrotropic solution may be a proper choice to preclude the 
use of organic solvents. UV/VIS spectroscopy is an 
instrumental technique of choice for the mentioned purpose 
in industrial laboratories due to its simplicity and ease of 
operation. Kitov Pharma announced that the Food and Drug 
Administration (FDA) has approved Consensi (amlodipine 
and celecoxib) for patients with osteoarthritis 
pain and hypertension. He trial used celecoxib capsules and 
amlodipine tablets that were individually over-encapsulated 
and then taken together or with matching placebos. Patients 
were randomized to 1 of 4 treatment arms: celecoxib 200mg 
+ amlodipine 10mg, amlodipine 10mg, celecoxib 200mg or 
placebo; all treatments were given once a day for 14 days. 
Results showed that the combination of celecoxib and 
amlodipine provided similar blood pressure reduction to an 
equal dose of amlodipine. We suppose that Consensi, as a 
single pill combination treatment for osteoarthritis and 
hypertension, presents a unique value proposition of 
potentially increasing treatment adherence44. Therefore, it 
was thought worthwhile to employ hydrotropic solution to 
extract out the drug from fine powder of marketed 
formulation to carry out spectrophotometric estimation. 
There are no reports yet for the determination of this 
combination by proposed methods. The present work 
emphasizes on the quantitative estimation of AMD and CLX 
in their combined dosage form by UV Spectroscopic 
methods. 
MATERIALS AND METHODS  
Pure sample of AMD and CLX was obtained as a gift sample 
from Matrix Laboratories, Mumbai and Reddy’s Labs, 
Hyderabad, India respectively. Sodium benzoate was 
obtained from Merck Chemical Division, Mumbai. All other 
chemicals used were of analytical grade. Reverse osmosis 
water was used throughout the study. In House synthetic 
mixture of AMD and CLX were prepared in the ratio of 
(10:200mg). Label claim of AMD and CLX in tablet is 10 and 
200mg respectively. A Labindia 3000+ UV/VIS 
spectrophotometer with 1 cm matched quartz cells was used 
for the estimation. 
 
Preliminary solubility studies of drugs  
Solubility of both drugs was determined at 25±1°C. An 
excess amount of drug was added to two screw capped 25 
ml of volumetric flasks containing different aqueous systems 
viz. distilled water and different combination of hydrotropic 
agent. The volumetric flasks were shaken mechanically for 
12 h at 25±1°C in a mechanical shaker. These solutions were 
allowed to equilibrate for next 24 hr and then centrifuged 
for 5 min at 2000 rpm. The supernatant liquid was taken for 
appropriate dilution after filtering through Whatman filter 
paper #41 and analyzed spectrophotometrically against 
water as blank. After analysis, it was found that the 
enhancement in the solubility of AMD and CLX was found to 
be more than 32 and 26 folds, respectively in a 2M sodium 
benzoate as compared to solubility studies in other solvents 
Selection of hydrotropic agent 
AMD and CLX were scanned in hydrotropic agent in the 
spectrum mode over the UV range 200-400 and 2M sodium 
benzoate solution was found to be most appropriate 
because:   
AMD and CLX are soluble in it (32 and 26 fold enhancement 
of solubility).  
AMD and CLX are stable in hydrotropic agent. 
AMD and CLX, both exhibit good spectral characteristics in it. 
Sodium benzoate has no interference with the λmax of AMD 
and CLX, 243and 255nm, respectively (Figure 2).  
 
Figure 2. Overlay spectra of AMD 8μg/ml and CLX 30 
μg/ml 
Establishment of stability profile 
Stability of AMD and CLX was observed by dissolving in a 2M 
sodium benzoate solution used as hydrotropic agent. 
Solution of AMD and CLX was scanned under time scan for 
30 min. Spectra of the drug under time scan shows that drug 
is stable in hydrotropic solution. 
Linearity range and calibration graph 
Preparation of standard stock solutions of AMD and CLX 
Standard stock solutions of 1000 μg/ml were prepared by 
dissolving separately 100 mg of each drug in hydrotropic 
solution and the flask was sonicated for about 10 min to 
solubilized the drug (Stock-A).  
Preparation of working standard solution for calibration 
curve  
The standard solution (1000μg/ml) was further diluted in 
different dilutions and prepared ranging from 2-10μg/ml for 
AMD and 10-50μg/ml for CLX. The calibration curve was 
plotted between concentrations and absorbances. Linearity 
data and result of their optical characteristics are shown in 
Table 1 
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Table 1 Optical characteristics and linearity data of AMD 
and CLX 
S. N. Parameters AMD CLX 
1 Working λ 243 255 
2 Beer’s law limit (μg/ml) 2-10 10-50 
3 Correlation coefficient (r2)* 0.9992 0.9995 
4 Slope (m)* 0.075 0.010 
5 Intercept (c)* 0.002 0.002 
6 LOD (μg/ml) 0.298 0.343 
7 LOQ (μg/ml) 0.081 0.734 
* Average of five determinations 
Study of overlay spectra of drugs and selection of method  
The spectra exhibit major absorbance maxima at 243 nm 
and 255 nm for AMD and CLX, respectively and isosbestic 
point at 250 nm Figure 2. Due to difference in absorbance 
maxima and having no interference with each other both 
drugs can be simultaneously estimated by the simultaneous 
equation method (Method A) and the Q-analysis method 
(Method B). 
Vierordt’s simultaneous equation method (Method 1)  
The wavelength 243 nm (λmax of AMD) and 255 nm (λmax of 
CLX) was selected. The absorbencies of AMD and CLX were 
measured at 243 nm and 255 nm. This method of analysis is 
based on the absorption of drugs X and Y at the wavelength 
maxima of the other. The quantification analysis of AMDand 
CLX in a binary mixture was performed by using Eqs (1) and 
(2). Where CX and CY are the concentrations of AMD and CLX, 
respectively in the diluted sample, ax1 and ax2 are 
absorptivities of AMD at λ1 and λ2, ay1 and ay2 are 
absorptivities of CLX at λ1 and λ2, respectively (Table 2). A1 
and A2 are the absorbances of samples at the 243 and 255 
nm, respectively45. 
CX =A2ay1- A1ay2/ax2ay1-ax1ay2                                           (1) 
CY= A1ax2 -A2ax1/ax2ay1 -ax1ay2                                          (2) 
Q-analysis method (Method 2) 
In this method absorbances of both the drugs were 
calculated at two selected wavelengths; among which λ1 is 
the wavelength of isoabsorptive point of both drugs and λ2 is 
the λmax of either drug among both drugs. From the 
overlain spectra wavelength 250 nm (isoabsorption point) 
and 243 (λmax of AMD) were selected for the study. The 
absorbencies at 250 nm and 243 nm for CLX were obtained 
and similarly for AMD absorbencies are measured at 250 nm 
and 243 nm. The concentrations of the individual 
components were calculated by using the following 
equations; 
CX = Qm- Qy/Qx -Qy×A1/ax1                                          (3) 
CY= Qm- Qy/Qy -Qx× A1/ax1                                           (4) 
Where Qm= A2/A1, A1 is absorbance of sample at 
isoabsorptive point, A2 is absorbance of sample at λmax of 
one of the two components. ax1 and ax2 represent 
absorptivities of AMD at λ1 and λ2 and ay1 and ay2 denote 
absorptivities of CLX at λ1 and λ2, respectively (Table 2); CX 
and CY are the concentrations of AMD and CLX, 
respectively45, 46. 
 
Table 2 Absorptivities of AMD (x) and CLX (y) at λ1 and λ2 
Drug Method-1 Method-2 
 243nm (λ1) 255nm (λ2) 250 nm (λ1) 243nm (λ2) 
AMD ax1 0.0248 ax2 0.0053 ax1 0.0179 ax2 0.0064 
CLX ay1 0.0229 ay2 0.0514 ay1 0.0434 ay2 0.0514 
     QX 0.2900 QY 1.4015 
N=5 
Analysis of in-house formulation 
Twenty in-house tablets of AMD and CLX were weighed and 
ground to a fine powder; amount equal to 10 mg of AMD was 
taken in a 100 ml volumetric flask. The CLX present in this 
amount of tablet powder was 200 mg. Then 80 ml of sodium 
benzoate solution was added and the flask was sonicated for 
about 10 min to solubilize the drug present in tablet powder 
and the volume was made up to the mark with hydrotropic 
solution. After sonication filtration was done through 
Whatman filter paper No. 41. Filtrate was collected and 
further diluted with RO water to get the final concentrations 
of both drugs in the working range. The absorbances of final 
dilutions were observed at selected wavelengths and the 
concentrations were obtained from the simultaneous 
equation method and the absorbance ratio method. The 
result of statistical evaluation of tablet analysis is reported 
in Table 3. 
 
Table 3 Results and statistical parameters for tablet analysis: In-house (AMD10/CLX-200) 
S. No. Drug Label claim Amount found Recovery%* S.D.* %COV* %COV* 
Method-1 AMD 10 9.874 98.74 0.912 0.923 0.168 
CLX 200 198.43 99.22 1.012 1.019 0.187 
Method-2 AMD 10 9.789 97.89 0.872 0.890 0.169 
CLX 200 198.98 99.49 0.903 0.453 0.161 
* Average of five determinations 
Validation of method 
The developed methods for simultaneous estimation of AMD 
and CLX were validated as per ICH guidelines (Linearity, 
Accuracy, Precision and Robustness) 47. 
Linearity  
Linearity of AMD and CLX was established by response 
ratios of drugs. Response ratio of both drugs was calculated 
by dividing the absorbance with respective concentration 
and then a graph was plotted between concentration and 
response ratio. 
Limit of detection (LOD) and limit of quantification (LOQ)  
The LOD and LOQ of AMD and CLX were determined by 
using standard deviation of the response and slope approach 
as defined in International Conference on Harmonization 
(ICH) guidelines. The limit of detection (LOD) and limit of 
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quantification (LOQ) for AMD and CLX were found to be 
0.298μg/ml, 0.081μg/ml and 0.343μg/ml, 0.734μg/ml, 
respectively (Table 1) indicating that the proposed UV 
method is highly sensitive. 
Accuracy  
The accuracy of the proposed methods was assessed by 
recovery studies at three different levels i.e., 80%, 100% and 
120%. The recovery studies were carried out by adding a 
known amount of standard solution of AMD and CLX to 
preanalyzed tablet solutions. The resulting solutions were 
then re-analyzed by proposed methods. Total amount of 
drug found and percentage recovery were calculated. 
Results of recovery studies are reported in Table 4.
 
Table 4 Results of recovery studies on marketed formulations 
Recovery level% % Recovery (Mean ± SD)* 
 Method-1 Method-2 
 AMD CLX AMD CLX 
80 99.05±0.284 95.20±0.101 99.42±0.475 98.39±1.023 
100 99.06±0.400 96.62±0.093 98.44±0.672 99.64±0.172 
120 99.83±0.308 95.08±0.086 97.74±0.451 98.54±0.673 
Mean 99.31±0.331 95.64±0.094 98.54±0.532   98.86±0.622 
* Average of five determination 
Precision 
Precision of the methods was studied at three levels as repeatability, intermediate precision (Day to Day and analyst to analyst) 
and reproducibility (Table 5 & 6).  
Table 5 Results of validation (Mean ± SD)  
Parameter Method-1 
Precision (Mean ± SD)* AMD % RSD CLX % RSD 
Repeatability 99.21±0.033 0.571 99.72±0.043 0.189 
Day to day 98.71±0.050 1.071 99.54±0.038 0.171 
Analyst to analyst 99.12±0.033 0.656 99.46±0.150 0.475 
Reproducibility 98.94±0.071 0.984 99.67±0.039 0.196 
* Average of five determinations 
 Table 6 Results of validation (Mean ± SD)  
Parameter Method-2 
Precision (Mean ± SD)* AMD % RSD CLX % RSD 
Repeatability 98.74 ± 0.61 0.618 98.84 ± 1.04 1.052 
Day to day 98.84 ± 1.04 1.052 99.51 ± 0.81 0.814 
Analyst to analyst 99.55 ± 0.93 0.934 98.55 ± 0.28 0.284 
Reproducibility 98.43 ± 0.88 0.894 98.78 ± 0.27 0.273 
* Average of five determinations 
RESULTS AND DISCUSSIONS 
Based on the solubility and stability and spectral 
characteristics of the drugs, 2M sodium benzoate was used 
as a hydrotropic solution. It was found that solubility 
enhancement of AMD and CLX was more than 32 and 26-
fold, respectively in hydrotropic solution as compared with 
distilled water. AMD and CLX show maximum absorbances 
at 243 and 255 nm, respectively. Sodium benzoate solution 
did not show any absorbance above 225nm and thus no 
interference in the estimation of drugs was seen. AMD and 
CLX follow Beer’s law in the concentration range of 2-
10μg/ml and 10-50μg/ml (r2=0.9992 and 0.9995). Method-1 
employs the simultaneous equation method using 243 and 
255nm as two analytical wavelengths; method-2 employs 
the absorption ratio method, which uses 255 and 243nm as 
two analytical wavelengths for estimation of AMD and CLX. 
The optimized methods showed good reproducibility and 
mean recovery with 99.31±0.331and 95.64±0.094in 
method-1 and 98.54±0.532and 98.86±0.622in method-2 for 
AMD and CLX respectively. The mean percent label claims of 
in-house tablet dosage were found to be 98.74± 0.912and 
99.22± 1.012in method-1, 97.89± 0.872and 99.49± 0.903 in 
method-2 for AMD and CLX, respectively. The standard 
deviation, coefficient of variance and standard error were 
obtained for AMD and CLX were satisfactorily low. Result of 
precision at different levels was found to be within 
acceptable limits (RSD < 2). 
CONCLUSION  
There was no interference of 2M sodium benzoate solution 
in the estimation and hence the two UV spectrophotometric 
methods were found to be simple, accurate, economic and 
rapid for simultaneous estimation of AMD and CLX in bulk 
and in-house tablet dosage forms. The proposed method can 
be successfully employed for the routine analysis of AMD 
and CLX containing dosage forms. 
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